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ARTICLE
Timing of Smarcb1 and Nf2 inactivation determines
schwannoma versus rhabdoid tumor development
Jeremie Vitte 1, Fuying Gao2, Giovanni Coppola 2, Alexander R. Judkins3 & Marco Giovannini 1
Germline mutations of the SMARCB1 gene predispose to two distinct tumor syndromes:
rhabdoid tumor predisposition syndrome, with malignant pediatric tumors mostly developing
in brain and kidney, and familial schwannomatosis, with adulthood benign tumors involving
cranial and peripheral nerves. The mechanisms by which SMARCB1 germline mutations
predispose to rhabdoid tumors versus schwannomas are still unknown. Here, to understand
the origin of these two types of SMARCB1-associated tumors, we generated different tissue-
and developmental stage-specific conditional knockout mice carrying Smarcb1 and/or Nf2
deletion. Smarcb1 loss in early neural crest was necessary to initiate tumorigenesis in the
cranial nerves and meninges with typical histological features and molecular profiles of
human rhabdoid tumors. By inducing Smarcb1 loss at later developmental stage in the
Schwann cell lineage, in addition to biallelic Nf2 gene inactivation, we generated the first
mouse model developing schwannomas with the same underlying gene mutations found in
schwannomatosis patients.
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Germline alterations of SMARCB1 gene predispose to twodifferent inherited tumor syndromes: rhabdoid tumorpredisposition syndrome (MIM 609322)1 and familial
schwannomatosis (MIM 162091)2. The first genetic evidence
of the role of SMARCB1 as a tumor suppressor was the identi-
fication of its biallelic mutations as the cause of most cases of
malignant rhabdoid tumors (RTs)3, 4, a highly aggressive pedia-
tric cancer that usually occurs in the brain (named atypical
teratoid rhabdoid tumor: AT/RT), kidneys and soft tissues in
the first years of life. Heterozygous SMARCB1 mutations are the
basis of the rhabdoid tumor predisposition syndrome3, 5. More
recently, SMARCB1 has been identified as a predisposing gene in
familial schwannomatosis6, a condition characterized by the onset
of multiple spinal, peripheral, and cranial-nerve schwannomas
during adulthood in the absence of vestibular schwannomas7.
Five percent of schwannomatosis patients also develop cranial or
spinal meningiomas8. SMARCB1 germline mutations have
been found in 45% of familial probands and 7% of sporadic
schwannomatosis patients9. Although the exact molecular
pathogenetic mechanisms in these schwannomas remain to be
elucidated, a 4-hit/3-step mechanism involving SMARCB1 and
NF2 genes seems to underlie development of these benign tumors
in schwannomatosis patients10. Germline mutations in LZTR1,
a gene closely linked to NF2 and SMARCB1 on chromosome 22,
have recently been identified in a significant proportion of
schwannomatosis patients lacking SMARCB1 germline muta-
tions. Similar to SMARCB1-related schwannomas, different
additional somatic mutations in NF2 were identified in schwan-
nomas from these patients, thus supporting the 4-hit/3-step
hypothesis11. This mechanism reinstates the crucial role of
biallelic NF2 loss in schwannoma genesis and of developmental
risk periods for SMARCB1 and NF2 mutations to occur. In
contrast, a single case of double SMARCB1/NF2 inactivation was
found in RTs12. Recent analysis of a larger series confirmed
SMARCB1 as the primary tumor suppressor gene involved in the
development of rhabdoid tumors with no recurrent additional
oncogenic canonical pathway mutations identified13. This raises
challenging questions about the molecular mechanisms by which
germline mutations in the same gene predispose to early
aggressive RTs versus late-onset benign PNS tumors. Analysis of
the SMARCB1 gene mutation spectrum points to genotype-
phenotype correlations, with germline rhabdoid tumor mutations
being more centrally placed in the coding sequence, involving
multiple exons and truncating mutations of the SMARCB1 gene.
Conversely, schwannomatosis mutations are mostly non
truncating mutations and located in hot spots at both 5′ and 3′
end of the SMARCB1 gene14. However, families with RTs or
multiple epitheloid schwannomas sharing the same SMARCB1
mutation have also been described15–17. A link between
schwannoma and RT has also been suggested by the histological
analysis of a series of aggressive PNS tumors revealing rhabdoid
features18–20, and sporadic case reports of RTs emanating from
cranial nerves21–23.
Altogether, these observations raise the question of whether
the two types of SMARCB1-deficient tumors arise from common
or different progenitor cells. In mice, the specific deletion of the
Nf2 gene in P0 permissive cells targets the cells of origin of
schwannomas in cranial nerves, peripheral nerves, and nerve
roots24, 25. Although different hypotheses have been suggested, the
cell of origin of RTs remains unclear. Different studies using
histological and molecular markers or mouse models suggested
that RTs could arise from the mesenchymal lineage26, neural
progenitor cells27, neural crest stem cells28–31, stem cells32, germ
and/or embryonic stem cells33. The homozygous inactivation of
Smarcb1 in mice leads to peri-implantation lethality and hetero-
zygous mice develop RTs at low penetrance (15–30%)29, 31, 34.
In two different Smarcb1+/− mouse models, RTs developed
predominantly in the soft tissues of the head and neck29, 34. In
another Smarcb1+/− model, 30% of the mice developed intra-
cranial tumors and 27% in the spinal cord around the dorsal
ganglia or spinal nerves that were classified as undifferentiated
sarcomas with variable rhabdoid features31. All three types of
Smarcb1+/− mice presented an extended time window for tumor
onset with the earlier appearance at 3–4 months of age and
median onset at 11–12 months of age, depending on the model29,
31, 34. Conditional Smarcb1 inactivation in all tissues except
the brain led to 100% of mice developing T-cell lymphoma
with 13% of mice developing RTs with a median latency
of 11 weeks after induction, demonstrating that inactivation of
the second Smarcb1 allele is rate limiting RT development in
Smarcb1+/− mice35.
To investigate the role of Smarcb1 loss in PNS tumorigenesis,
we conditionally inactivated Smarcb1 in neural crest (NC) and
Schwann cell (SC) lineages. We report that tumors arising
from neural crest cells (NCCs) have histological and molecular
characteristics of human RTs, providing novel clues to their
cellular origin. Finally, we show that biallelic inactivation of
Smarcb1 and Nf2 in SCs results in benign schwannoma, and not
in RT, thus re-emphasizing the necessary and sufficient role of
NF2 loss in SC tumorigenesis, in both neurofibromatosis type 2
(NF2) and schwannomatosis, and the existence of a critical
developmental risk period for SMARCB1-deficient RTs to occur.
Results
Smarcb1 loss in early NC promotes RT development. We tested
the hypothesis that Smarcb1 inactivation in NCCs and in the
SC lineage is sufficient to initiate schwannoma development in
the mouse. Fifty percent of mice (3/6) carrying a germline
Smarcb1 deleted allele (Smarcb1del/+) developed tumors with
rhabdoid features occurring over a wide age range (2–17 months
of age). This observation is in line with the tumor phenotype
described in other mouse models of Smarcb1 inactivation29, 31, 34.
Tumors were located in the brain (emergence of trigeminal
nerve), spinal nerve roots and on the cheek and did not present
histological features of schwannoma. To circumvent the early
lethality of Smarcb1−/− mutants and malignant tumors found in
Smarcb1del/+ mice, we used a conditional floxed Smarcb1 allele
(Smarcb1flox)36. To define the temporal window of susceptibility
to Smarcb1 loss, we used different promoters to induce Cre-
mediated Smarcb1 deletion at different stages of SC development.
To specifically direct Cre recombinase expression to the NCCs at
E9.5 and SC lineage we chose the promoter of the protein
zero (P0) gene, which efficiently targets schwannoma precursor
cells24, 25. P0-CreC;Smarcb1flox/flox mice, harboring a homozygous
deletion of Smarcb1, were viable and obtained at the expected
Mendelian ratio (21.6 vs. 25%, non-statistically significant
difference, Fig. 1a).
P0-CreC;Smarcb1flox/flox mice presented with mild craniofacial
abnormalities: orbit malformations and misshapen mandibles,
with dental malocclusion eventually leading to outgrowing
teeth. Few mice displayed bloated intestines with histological
analysis revealing emaciated intestine wall associated with a
reduced number of villi. About 65% of P0-CreC;Smarcb1flox/flox
mice developed tumors between 1.5 and 5 months of age with
an overall median survival of 3.2 months (Fig. 1b). These
mice developed aggressive cranial nerve tumors: olfactory
(91%, Fig. 1c, f, g), trigeminal (51%, Fig. 1i), oculomotor and
optic (37%, Fig. 1m), or vestibulocochlear (14%, Fig. 1k, l) nerves
were the most affected. Tumors were also found in the meninges
with variable extent of brain invasion (14%, Fig. 2a, b), in spinal
nerve roots (3%, Fig. 1n) and occasionally in the eye (Fig. 1m),
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with 62.5% (15/24) of the mice displaying multiple tumors at
dissection. In all mice presenting with a head tilt and/or spinning
behavior, unilateral tumors of the vestibular nerve ganglion
and/or invasion of the inner ear were found (Fig. 1k, l). Use of the
P0-CreB transgenic mice, which express Cre recombinase at E9.5,
similarly to P0-CreC, but in a larger number of cells25, resulted
in a more severe phenotype with a lower percentage of viable
P0-CreB;Smarcb1flox/flox mice (1.4 vs. 25% expected, P< 0.0001,
Supplementary Fig. 1a). Nasal cavity or retro-orbital tumors, with
the same histological features than P0-CreC;Smarcb1flox/flox
tumors were found in 62.5% of P0-CreB;Smarcb1flox/flox mice
between 1.2 and 2 months of age (Supplementary Fig. 1b). Tumor
location in P0-CreC;Smarcb1flox/flox mice correlated with the
expression pattern of the P0-CreC transgene (Supplementary
Fig. 2a). X-gal staining of olfactory epithelium (Fig. 1h) and
trigeminal nerve (Fig. 1j) in P0-CreC;ACZL mice25 demonstrated
the presence of Cre activity in few cells that are likely the cells
of origin of tumors in P0-CreC;Smarcb1flox/flox mice. Tumors
developed by P0-CreC;Smarcb1flox/flox;ACZL mice before
10 months of age displayed a blue X-gal staining, demonstrating
the Cre recombinase activity and Smarcb1 deletion, including in
rhabdoid cells (Fig. 1d). The presence of the Smarcb1 deleted
allele in all tumors from symptomatic P0-CreC;Smarcb1flox/flox
mice was confirmed by PCR analysis (Fig. 1e). Despite expression
of the Cre recombinase and detection of the Smarcb1 deleted
allele, tumors were not found in kidneys, gonads and in brachial,
saphenous and sciatic nerves of P0-CreC;Smarcb1flox/+ and
P0-CreC;Smarcb1flox/flox mice (Supplementary Fig. 2a, b). This
finding can be explained either by the fact that Cre in P0-CreC
and P0-CreB mice is not expressed in the cell of origin of kidney
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Fig. 1 P0-CreC;Smarcb1flox/flox mice develop RTs in NC-derived tissues. a Genotype distribution of mice at 3 weeks of age (n= 282) born from crossings of
P0-CreC;Smarcb1flox/+ and Smarcb1flox/flox mice. b Kaplan–Meier curve representing the percent survival of P0-CreC;Smarcb1flox/flox (n= 141, median survival
= 3.2 months), P0-CreC;Smarcb1flox/+ (n= 29, median survival= 21.6 months) and Smarcb1flox/flox (n= 33, median survival> 24 months) mice versus age in
months. c T2-weighted MR image identifying a tumor mass in the nasal cavities of a P0-CreC;Smarcb1flox/flox mouse (arrow). d X-gal staining of a
tumor from P0-CreC;Smarcb1flox/flox;ACZL mice demonstrating activation of the beta-galactosidase reporter gene ACZL (blue staining) thus attesting for
Smarcb1 deletion throughout the tumor and in rhabdoid cells (arrow and inset). e Smarcb1del allele is detected in all the tumors from young P0-CreC;
Smarcb1flox/flox mice (< 10 months of age). Long-term P0-CreC;Smarcb1flox/flox survivor mice (Supplementary Fig. 2c) develop liver, lung, and uterus tumors,
with no deletion of Smarcb1 similar to control littermates (Smarcb1flox/flox). These tumors are part of the normal tumor spectrum of aging FVB/N mice24.
f, g P0-CreC;Smarcb1flox/flox mice develop tumors along the olfactory nerve (arrow), close to the olfactory bulb (f) or in the nasal cavity below the olfactory
epithelium (double arrow, g). h X-gal staining of the nasal cavity of a P0-CreC;AZCL mouse showing specific Cre recombinase expression in SCs of the
olfactory nerve (arrow) below the olfactory epithelium layer (double arrow). i Tumor of the trigeminal nerve (transversal section). j X-gal staining of
the trigeminal nerve of a P0-CreC;AZCL mouse showing specific Cre recombinase expression in SCs (arrows). k Tumor of the vestibulocochlear nerve
(dashed square) invading the cochlea (arrow). Note that the contralateral side is not affected. l Detail of the vestibulocochlear nerve tumor shown in k.
m Tumors in the eye (black arrow), optic nerve (white arrow), and oculomotor nerve (striped arrow) of a P0-CreC;Smarcb1flox/flox mouse. n Tumors in
the spinal nerve roots (arrows, longitudinal section). Insets in f, i, l, m and n represent a higher magnification of the dashed square area (insets scale bar is
20 µm). **(P< 0.01) and ***(P< 0.001); log-rank (Mantel–Cox) test
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RTs, or is not expressed during the specific temporal window of
vulnerability to RT development. No pathological alteration was
found in nerves (cranial, phrenic, saphenous, sciatic nerves, and
brachial plexus), DRGs and brain in long-term P0-CreC;
Smarcb1flox/flox survivor mice (up to 24 months of age).
P0-CreC;Smarcb1flox/flox tumors display human RT features.
Tumors of P0-CreC;Smarcb1flox/flox mice displayed a histologic
spectrum ranging from a primitive neuroectodermal (Fig. 3a),
to a mesenchymal (Fig. 3b) or rhabdoid pattern (Fig. 3c). No
epithelial differentiation was observed. Most tumor cells exhibited
atypical large nuclei with vesicular chromatin, irregular and
thick membrane, and prominent nucleoli (Fig. 3b inset). Some of
these cells showed an eccentric nucleus associated with a
prominent eosinophilic cytoplasmic inclusion (Fig. 3c and inset)
or cytoplasmic vacuolar degeneration (Fig. 3d and inset), typical
histological features encountered in human AT/RTs37. Rhabdoid
features or scattered rhabdoid cells were found in all analyzed
tumors, and in 30% of these, nests of rhabdoid cells were present
(Fig. 3c). Bi-nucleated and giant multinucleated cells were also
found in some tumors. Tumors displayed different patterns
depending on their size at the time of dissection. Larger tumors
typically presented more rhabdoid features than smaller tumors.
All the tumors examined demonstrated loss of SMARCB1 nuclear
expression by immunohistochemical staining (Fig. 3e). However,
similar to human RTs38, infiltrating inflammatory and endothe-
lial cells retained SMARCB1 staining (Fig. 3e). The tumors
behaved in an aggressive manner, displaying rapid growth,
moderate to high cellularity and abundant mitotic figures
with high percentages of Ki-67-positive cells (50.7± 3.7% in
neuroectodermal and 33.4± 3.9% in mesenchymal histological
subtypes) (Fig. 3f). Larger tumors frequently showed areas of
necrosis. Some tumors were contained within the boundaries of
the tissue of origin, such as the epineurium of the trigeminal
nerve (Fig. 1i), while other tumors, such as those extending in the
cochlea from the vestibulocochlear nerve, were more invasive,
(Fig. 1k, l). Supratentorial rhabdoid tumors were found
predominantly located in the subarachnoid space with extension
into the brain parenchyma (Fig. 2a, b). These tumors displayed
well-demarcated smooth borders with adjacent tissues and
reactive gliosis confirmed with GFAP staining in adjacent tissues
to the tumor (Fig. 2d). In some cases, individual tumor cells were
invading the brain parenchyma (Fig. 2e). The location of these
tumors suggested that they originated outside of the brain
parenchyma and developed from the cranial NC-derived
meningeal progenitor cells39. The absence of PGDS staining
(Fig. 2c), an arachnoid cell marker expressed postnatally in the
NC-derived meninges, substantiates the hypothesis that menin-
geal RTs originate from early NC-derived progenitor cells, before
differentiation in PGDS-positive arachnoid cells39.
Because of their heterogeneous histologic features, RTs usually
show a broad spectrum of immunohistochemical reactivity40.
With a remarkable similarity to human RTs37, tumors from
P0-CreC;Smarcb1flox/flox mice typically showed a consistent
expression of vimentin (Fig. 3g), a moderate to strong SMA
staining (Fig. 3h), whereas staining for cytokeratin proteins or
neurofilament triplet proteins, commonly found in foci of human
AT/RTs, was not detected (Fig. 3i, j). Staining of S100 protein,
a marker of schwannoma41, allowed to clearly distinguish the
P0-CreC;Smarcb1flox/flox mouse tumors from schwannomas:
unlike schwannomas from P0-CreC;Nf2flox/flox mice, which
strongly and diffusely express S100 protein (Fig. 3k), tumor cells
from P0-CreC;Smarcb1flox/flox mice showed no S100 protein by
IHC (Fig. 3l). Modest GFAP expression was present in P0-CreC;
Nf2flox/flox tumors (Fig. 3m) whereas P0-CreC;Smarcb1flox/flox
tumors showed little GFAP expression in few reactive astrocytes
(Fig. 3n). However, tumors from both P0-CreC;Smarcb1flox/flox
and P0-CreC;Nf2flox/flox mice displayed a strong staining for
FABP7 (Fatty Acid Binding Protein 7) (Fig. 3o, p), an early
marker of SC precursors42. Altogether, P0-CreC;Smarcb1flox/flox
mouse tumors displayed typical histological and immunohisto-
chemical features of human RTs, clearly distinguishable from
Nf2-deficient P0-CreC;Nf2flox/flox schwannomas (Fig. 3 and
Supplementary Table 1)37.
Molecular profiling classifies mouse RTs in three subgroups.
To address the relevance of the P0-CreC;Smarcb1flox/flox
mouse tumors as models of the human condition, we profiled 12
representative RTs by whole-genome RNA sequencing. Unsu-
pervised hierarchical clustering of the top 5000 most variable
transcripts in P0-CreC;Smarcb1flox/flox RTs identified three mole-
cular subgroups (Supplementary Fig. 3a). Based on the maximum
cophenetic correlation score (non-negative matrix factorization
(NMF) method), the optimal number of clusters was estimated to
be two or three (Supplementary Fig. 3b, c). Across species unsu-
pervised cluster analysis of the top 5000 most variable transcripts
in P0-CreC;Smarcb1flox/flox and human RTs from Johann et al.,
showed that mouse tumors distributed among the three recently
identified human AT/RT molecular subgroups43, independent of
their anatomical origin (Fig. 4a). Thus, tumors from P0-CreC;
Smarcb1flox/flox mice recapitulate the molecular diversity of human
AT/RTs. According to their inclusion in different human AT/RT
clusters, we attributed similar molecular subgroups to the P0-
CreC;Smarcb1flox/flox RTs (mRT-Myc, mRT-Shh or mRT-Tyr). In
GFAP
200 µm100 µm
PGDS GFAP
100 µm
100 µm1 mm200 µm
ba
edc
Fig. 2 P0-CreC;Smarcb1flox/flox mice develop RTs in the meninges.
a Supratentorial tumors (white arrow) were found predominantly located in
the subarachnoid space (black arrow, inset) with extension into the brain
parenchyma. Inset represents a higher magnification of the dashed square
area. b Detail of a tumor originating from the meninges. The arrow shows
the arachnoid cell layer. c No PGDS staining was found in the tumor as
opposed to the arachnoid cell layer (arrow). d, e The GFAP staining
demonstrated the different degree (d, non-invasive; e, irregular tumor brain
interface consistent with infiltration) of invasiveness of the tumors in the
brain tissue
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a unsupervised cluster analysis of gene expression profiles from
P0-CreC;Smarcb1flox/flox, Rosa26-CreERT2;Smarcb1flox/flox30 and
hGFAP-Cre;Smarcb1flox/flox;Trp53flox/flox44 RT mouse models,
tumors segregated based on molecular subgroups rather than on
the model of origin, demonstrating their molecular analogy
(Fig. 4b). We conducted Weighted Gene Co-expression Network
Analysis (WGCNA), a systems biology approach used to identify
networks of co-expressed genes in relation to phenotypic data,
using the R package. WGCNA allowed identification, within
the highest positively correlated module with each molecular
subgroup, of several representative marker genes that were
significantly and consistently overexpressed in both human and
mouse RT molecular subgroups (Fig. 4c). Specifically, TRPM3
(Transient Receptor Potential cation channel subfamily M
member 3), a membrane channel that can promote renal cell
tumors45, was found consistently overexpressed in the human
hTYR and mouse mRT-Tyr molecular subgroups (Fig. 4c).
HDGFRP3 (Hepatoma-Derived Growth Factor, Related
Protein 3), which plays an essential role in hepatocellular
carcinoma pathogenesis46 and LOXL4 (Lysyl Oxidase Like 4),
which promotes proliferation and metastasis of gastric cancer47,
were consistently overexpressed in mouse and human SHH and
MYC molecular subgroups, respectively (Fig. 4c). TYR, MYCN,
and HOTAIR, marker genes of the three human subgroups43
showed a similar trend of overexpression in the respective mouse
RT subgroups, albeit not statistically significant likely due to the
small number of mouse tumors analyzed (Fig. 4c).
As in human AT/RTs48, Smarcb1 deficiency in all P0-CreC;
Smarcb1flox/flox RT subgroups was correlated with an increased
expression of the polycomb gene Ezh2 (Supplementary Fig. 4a, b), a
key driver of oncogenesis49. Analysis of molecular pathways in P0-
CreC;Smarcb1flox/flox RTs by western blot showed increased
phosphorylation of Akt, S6, and 4E-BP1, consistent with activation
of the mTOR/Akt pathway, similar to schwannomas in P0-CreC;
Nf2flox/flox mice (Supplementary Fig. 4c). Cell cycle proteins (CDK4,
CDK6, cyclin D1, p16) were overexpressed in all P0-CreC;
Smarcb1flox/flox tumors and phosphorylation of the retinoblastoma
protein was found in 3 out of 5 RTs (Supplementary Fig. 4c).
Activation of these pathways has been reported in human RTs50.
Early NC molecular signature in Smarcb1-deficient RTs. To
explore the effect of Smarcb1 deficiency on the SWI/SNF complex
in P0-CreC;Smarcb1flox/flox mouse RTs, we analyzed the
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Fig. 3 RTs of P0-CreC;Smarcb1flox/flox mice display typical histological and immunohistochemical staining features of human RTs. a Tumor presenting a
primitive neuroectodermal pattern. b Tumor with mesenchymal pattern characterized by spindle-shaped cell component and nuclei showing vesicular
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expression of the different complex subunits using the RNA-Seq
gene expression data. High expression of Actl6a (BAF53a), Phf10
(BAF45a), Dpf2 (BAF45d), and Ss18 (SYT) genes, encoding
subunits found in the pluripotent embryonic stem cell (esBAF)
and in the multipotent neural progenitor (npBAF) complexes51
was found in RTs of all three molecular subgroups (Fig. 4d). In
contrast, mouse RTs did not express Actl6b (BAF43b), Dpf1
(BAF45b), Dpf3 (BAF45c) and Ss18l1 (CREST) genes, encoding
subunits exclusively found in the postmitotic neural BAF complex
(nBAF) (Fig. 4d). These results, except for SS18L1 (CREST), were
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consistent with subunit gene expression in the series of human
AT/RTs from Johann et al. (Fig. 4e) and demonstrated that
the residual SWI/SNF complex in Smarcb1-deficient RTs is
characteristic of undifferentiated progenitor cells51, pointing to an
early developmental cell population of origin for RTs. Analysis of
gene regulatory networks underlying formation of NCCs showed
robust expression of genes exclusively expressed in the neural plate
border and NC specification modules52 in both P0-CreC;
Smarcb1flox/flox and human RT samples (Fig. 4f, g). The fact
that human AT/RTs and RTs from P0-CreC;Smarcb1flox/flox
mice retain specific marker genes of early NC formation, strongly
corroborates the hypothesis of an early NCC as their cell of origin.
SC differentiation suppresses Smarcb1-driven tumorigenicity.
The existence of adult carriers of a SMARCB1 mutation without
RT in families presenting either RTs or schwannomas suggests
the existence of a specific developmental time window during
which RT progenitor cells are vulnerable to SMARCB1 loss15–17.
To assess if loss of Smarcb1 at a later stage of development would
induce tumorigenesis, we bred Smarcb1flox mice with DHH-Cre
and mGFAP-Cre transgenic mice that express the Cre recombi-
nase at later stages of SC development. DHH-Cre transgenic
mice53 express Cre in SC precursors beginning at embryonic day
E12.542. DHH-Cre;Smarcb1flox/flox mice had an overall median
survival of 3 weeks and displayed progressive hindlimb paralysis.
The sciatic nerves were thinner and more transparent than in
control littermates. Histological analysis demonstrated that loss
of Smarcb1 (Supplementary Fig. 5c, d) led to a lack of structure
and organization of the nerve fibers (Supplementary Fig. 5a, b)
with increased numbers of BrdU and Ki-67 positive cells
(Supplementary Fig. 5e–h). No tumors were found in cranial
nerves, peripheral nerves, or dorsal root ganglions (DRGs) of
DHH-Cre;Smarcb1flox/flox mice during their short lifespan.
To target immature SCs, we generated mGFAP-Cre;
Smarcb1flox/flox mice using the mGFAP-Cre transgenic mice that
express the Cre recombinase under the promoter of the mouse
GFAP gene54. This promoter targets immature SCs in the
peripheral nervous system starting at E13.554, postnatal astrocytes
throughout the CNS and postnatal astroglial cells in the
cerebellum55. X-gal staining of tissues from mGFAP-Cre;ACZL
mice demonstrated expression of Cre recombinase in spinal
nerve root SCs (Supplementary Fig. 6d), spinal cord and
throughout the brain (Supplementary Fig. 6c). At three months of
age, mGFAP-Cre;Smarcb1flox/flox and mGFAP-Cre;Smarcb1del/flox
mice started developing cataracts, displayed progressive ataxia
with loss of motor coordination and gait balance, eventually
leading to loss of bodyweight and euthanasia. This neurological
phenotype was similar to the one described at earlier age
in hGFAP-Cre;Smarcb1flox/flox56 and hGFAP-Cre;Smarcb1flox/flox;
Trp53flox/flox44 mice. The median survival of mGFAP-Cre;
Smarcb1flox/flox and mGFAP-Cre;Smarcb1del/flox mice was 3.7
and 3.8 months of age (P= 0.74, non-statistically significant
difference, Supplementary Fig. 6b), respectively. Histological
analysis of the brain revealed atrophy of the cerebellum, but
no tumors were found in the brain, cranial nerves or DRGs
(Supplementary Fig. 6e, f). No change in cellularity was found in
the DRGs of mGFAP-Cre;Smarcb1flox/flox mice compared with
control littermates (Fig. 5a, b, g).
In conclusion, the observation that DHH-Cre;Smarcb1flox/flox
and mGFAP-Cre;Smarcb1flox/flox mice did not develop RTs
allowed us to narrow down to early NC development the time
window for Smarcb1 loss to promote malignant tumorigenesis.
Smarcb1 and Nf2 loss in SCs promotes schwannoma develop-
ment. The observation of frequent somatic, tumor-specific NF2
mutations, and the loss of the second NF2 allele in schwannomas
from patients with germline SMARCB1 mutations10, 57–59
strongly suggest that the classical two-hit model of tumorigenesis
does not pertain in the tumors of schwannomatosis patients, as it
would require biallelic SMARCB1 inactivation to be sufficient for
tumor initiation or growth7. Thus, we tested the hypothesis that
NF2 loss is necessary for schwannoma formation in schwanno-
matosis patients with germline SMARCB1 mutations.
To model the different steps leading to the double SMARCB1/
NF2 gene loss, we generated combinatorial Smarcb1 and Nf2
wild-type or mutant alleles, representative of the 4-hit/3-step
model. P0-CreC;Smarcb1flox/flox;Nf2flox/flox mice were not viable,
demonstrating that loss of both Smarcb1 and Nf2 during early
development is lethal. However, in mGFAP-Cre;Smarcb1flox/flox;
Nf2flox/flox mice, combination of Smarcb1 and Nf2 inactivation
resulted in viable mice, with a median survival of 6.4 months of
age. The statistically significant longer survival is due to the fact
that these mice do not develop the rapidly growing RTs inevitably
causing death in P0-CreC;Smarcb1flox/flox mice. Cre is expressed
in the DRGs of mGFAP-Cre mice starting at E13.554. The
mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox mice developed tumorlets
consisting of whorls of SCs in the DRGs (Fig. 5e). These DRG
lesions are similar to those described in the P0-CreC;Nf2flox/flox25
and mGFAP-Cre;Nf2flox/flox mice, and are reminiscent of the
schwannoma tumorlets found in NF2 patients60, thus
demonstrating the necessary role of Nf2 loss for schwannoma
formation. Schwannoma tumorlets in the DRGs of mGFAP-Cre;
Smarcb1flox/flox;Nf2flox/flox mice were negative for SMARCB1 and
merlin staining, about 60% were positive for S100 protein
staining, and all were positive for GFAP and FABP7 (Fig. 6).
The mGFAP-Cre;Smarcb1flox/flox;Nf2flox/+ mice showed similar
Fig. 4 Molecular profiling of RTs from P0-CreC;Smarcb1flox/flox mice. a Unsupervised hierarchical clustering of gene expression profiles from 12 P0-CreC;
Smarcb1flox/flox mouse tumors and 49 human AT/RTs43 using the 5,000 most variable transcripts. The P0-CreC;Smarcb1flox/flox tumors distributed among
the three human AT/RT molecular subgroups. Information about tumor molecular subgroups and anatomical location is displayed in the lower bars.
b Unsupervised hierarchical clustering of gene expression profiles from 12 P0-CreC;Smarcb1flox/flox mouse tumors, eight tumors from the tamoxifen
inducible Rosa26-CreERT2;Smarcb1flox/flox mouse model30 and five tumors from the hGFAP-Cre;Smarcb1flox/flox;Trp53flox/flox mouse model44 using the 5,000
most differentially expressed genes. Information about tumor molecular subgroups is displayed in the lower bars. c Normalized expression level of
representative genes for both of the three human AT/RT molecular subgroups: hTYR (n= 16), hSHH (n= 16), and hMYC (n= 17) and the three P0-CreC;
Smarcb1flox/flox RT molecular subgroups: mRT-Tyr (n= 5), mRT-Shh (n= 4) and mRT-Myc (n= 3). On the basis of the cluster analysis in (a), we
respectively named hMYC, hSHH and hTYR the three tumor subgroups including human tumors from the MYC, SHH and TYR molecular subgroups 43.
The P-value indicates the statistical significance of gene enrichment within their respective WGCNA module for each respective molecular subgroup.
d–g Gene expression levels of specific SWI/SNF complex subunits (d, e) and NC developmental markers (f, g) in the three molecular subgroups of P0-
CreC;Smarcb1flox/flox RTs (d, f) and human AT/RTs (e, g). d, f RNA-Seq data are expressed in RPKM (Reads Per Kilobase of transcript per Million mapped
reads). e, g graphs of microarray gene-expression intensity from dataset GSE70678. c–g RNA-Seq and microarray gene expression levels are shown using
Tukey boxplots: the central lines represent the median, boxes (interquartile range or IQR) represent 50% of data ranging from the 25 to 75% quantile,
whiskers represent extremes up to 1.5-fold box size, circles show outliers
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phenotype to mGFAP-Cre; Smarcb1flox/flox;Nf2flox/flox mice
(cataracts, impaired motor coordination and gait balance),
leading to a median survival of 7.1 months of age. Similarly to
mGFAP-Cre;Smarcb1flox/flox mice, the decreased and altered
mobility of mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox and mGFAP-
Cre;Smarcb1flox/flox;Nf2flox/+ mice led to bodyweight loss and
euthanasia. Interestingly, no schwannoma tumorlets were found
in the DRGs of mGFAP-Cre;Smarcb1flox/flox;Nf2flox/+ mice, which
contained similar cellularity as DRGs of Smarcb1flox/flox;
Nf2flox/flox control mice (0.0028 vs. 0.0028 cells/µm2, P= 0.94)
(Fig. 5c, d, g) and mGFAP-Cre;Smarcb1flox/flox mice (0.0028 vs.
0.0026 cells/µm2, P= 0.35) (Fig. 5b, d, g). However, DRGs of
mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox mice showed a signifi-
cantly increased cellularity compared to those of mGFAP-Cre;
Smarcb1flox/flox;Nf2flox/+ mice (0.0044 vs. 0.0028 cells/µm2,
P= 0.0008) (Fig. 5d, e, g), thus demonstrating the crucial and
necessary role of biallelic Nf2 loss for schwannoma formation.
Ki-67 staining identified the presence of few proliferating cells
in the DRGs, including in the mGFAP-Cre;Smarcb1flox/flox;
Nf2flox/flox and mGFAP-Cre;Nf2flox/flox schwannoma tumorlets
(Fig. 6). Surprisingly, complete loss of Smarcb1 in the mGFAP-
Cre;Smarcb1flox/flox;Nf2flox/flox tumors did not result in increased
cell proliferation compared to schwannoma tumorlets in DRGs
from mGFAP-Cre;Nf2flox/flox mice (Fig. 5f, g). The very low
percentage of proliferating cells in the DRGs of mGFAP-Cre;
Smarcb1flox/flox;Nf2flox/flox mice reflects the benign nature of these
tumors compared with malignant RTs in P0-CreC;Smarcb1flox/flox
mice (Figs. 3, 5 and 6).
Discussion
Patients with germline mutations of the SMARCB1 gene are
predisposed to develop RTs or schwannomas, two tumor
types with dramatically different clinical features. However,
the presence of aggressive PNS tumors with rhabdoid
features suggests a link between the development of RTs and
schwannomas20. We used the P0-CreC mouse line, known to
express the Cre recombinase in NCCs, to target the precursors
of the SC lineage and the schwannoma cells of origin42 (Fig. 7).
The early onset and high penetrance of RTs in P0-CreC;
Smarcb1flox/flox mice demonstrated that loss of Smarcb1 in early
NC (E9.5) is necessary for RT tumorigenesis (Fig. 7). This result is
consistent with the high penetrance of AT/RTs in Rosa26-
CreERT2;Smarcb1flox/flox mice injected with tamoxifen between
E6 and E1030. Although the Rosa26-CreERT2 model doesn’t
target Smarcb1 deletion in a specific cell type, expression profiling
suggests that the cell of origin could be ectomesenchyme, a
cephalic NCC-derived mesoderm or neural progenitors depend-
ing of the tumor subtype30. Inactivation of Smarcb1 at later stages
of SC development failed to initiate tumorigenesis in DHH-Cre;
Smarcb1flox/flox and mGFAP-Cre;Smarcb1flox/flox mice suggesting
that Smarcb1 loss is not tumorigenic in the peripheral SC
lineage or in the brain glial cells when the deletion is induced after
E12.5 or E13.5, respectively (Fig. 7); or that the neurological
deficits were lethal before the mice developed tumors. This
result is consistent with other studies demonstrating that single
loss of Smarcb1 in hGFAP-positive neural precursors is not
tumorigenic44, 56 and that additional loss of Trp53 is required to
induce AT/RT development in hGFAP-Cre;Smarcb1flox/flox;
Trp53flox/flox mice44. The use of different Cre drivers allowed us
to narrow down the temporal window during which Smarcb1 loss
is tumorigenic. The existence of a specific developmental
time window could also explain the presence of RTs and
schwannomatosis within a family sharing the same SMARCB1
mutation15–17. The neurological deficits developed by DHH-
CreC;Smarcb1flox/flox, mGFAP-Cre;Smarcb1flox/flox and mGFAP-
Cre;Smarcb1del/flox mice with late Smarcb1 inactivation also point
to a role of Smarcb1 in nervous system development, which could
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Fig. 5 Biallelic loss of Nf2 is necessary to induce schwannoma formation. a, b No difference in cellularity of DRGs from mGFAP-Cre;Smarcb1flox/flox mice (b)
compared with Smarcb1flox/flox control mice (a). c–f The loss of one additional Nf2 allele in mGFAP-Cre;Smarcb1flox/flox;Nf2flox/+ mice does not impair the DRG
cellularity (d) compared to mGFAP-Cre;Smarcb1flox/flox mice (b) or Smarcb1flox/flox;Nf2flox/flox control mice (c). The biallelic loss Nf2 induced the formation of
schwannoma tumorlets in mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox mice (e), similar to mGFAP-Cre;Nf2flox/flox mice (f). g Number of cells per DRG surface for each
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underlie the neurological deficits found in the SMARCB1-related
human Coffin–Siris syndrome61.
The fact that most of the tumors were found in the head of P0-
CreC;Smarcb1flox/flox mice is consistent with early Cre expression
under the control of the P0 promoter in cranial NCCs and the
prominent expression of Smarcb1 between E8 and E11.5 during
the embryonic development of the headfolds, neural folds and
first brachial arch34. P0 was originally identified as a SC-specific
myelin structural protein, but was more recently found expressed
by migrating NCCs in the head of E10.5 mouse embryos62, as well
as in the otic placode and migrating cranial NCCs of E10 rat
embryos. After E11, P0 can be detected in the ophthalmic and
submandibular branches of the trigeminal nerves, within the
trigeminal ganglion and in the developing acoustic/facial nerves
of rat embryos. The P0-CreC transgene used in this study is
expressed in the head of mouse embryos as early as E9.525. The
presence of craniofacial abnormalities confirms the early
inactivation of Smarcb1 in the cranial NC, which is at the
origin of multiple head structures such as bones and cartilages,
SCs, olfactory ensheathing cells and meninges. The high
frequency of tumors originating in the olfactory nerve is likely
due to the fact that olfactory ensheathing cells, as opposed to the
non-myelinating SCs of the trunk, do not down regulate P0
expression. Therefore, the promoter driving the Cre recombinase
is continuously activated in the olfactory ensheathing cells of
P0-CreC;Smarcb1flox/flox mice. Activity of the P0-Cre transgene
has also been demonstrated in the enteric ganglia63, thus
explaining the presence of bloated intestine resulting from defects
of the enteric nervous system, which is derived from vagal
and sacral NCCs. The presence of RTs in the subarachnoid space,
in the rostral part of the cortex is consistent with the hypothesis
that these tumors developed from the cranial NC-derived
meningeal progenitor cells39. Although in patients AT/RTs
are predominantly infratentorial, they can also develop in the
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supratentorial region of the brain with frequent connection to the
ventricles64. Human RTs have also been described in the
meninges65. The early NC origin of P0-CreC;Smarcb1flox/flox RTs
is also supported by expression of early NC specification markers
and SWI-SNF subunits characteristic of undifferentiated cells.
Altogether, these results strongly support the hypothesis that both
PNS and meningeal RTs originate from NCCs.
Tumors found in P0-CreC;Smarcb1flox/flox mice displayed
histological features strikingly similar to human RTs, including
aggressive growth, characteristic histological patterns
and presence of rhabdoid cells40. The anatomical locations of
RTs in P0-CreC;Smarcb1flox/flox mice have all been described
in human RT patients: optic22, oculomotor66, trigeminal21,
vestibulochochlear23 nerves, eye67, nasal cavities68, meninges65
and spine69. About 60% of P0-CreC;Smarcb1flox/flox mice
displayed multiple tumors at the time of dissection, which is
consistent with the occurrence of synchronous RTs in some
patients with SMARCB1 mutations66. Finally, molecular profiling
showed that P0-CreC;Smarcb1flox/flox RTs represented the full
spectrum of human AT/RT molecular subtypes43.
Although in mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox mice loss
of Smarcb1 and Nf2 is synchronous and not sequential as
postulated by the 4-hit/3-step model, this is the first tumor model
reproducing the genetic profile of schwannomatosis-
schwannomas with concomitant loss of both Smarcb1 and Nf2
genes, with schwannoma and no RT development (Fig. 7). The
mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox mouse model demon-
strates that biallelic loss of Smarcb1 loss is dispensable and Nf2
loss is necessary for schwannoma development41, as in mGFAP-
Cre;Nf2flox/flox mice. This is consistent with the presence of NF2
somatic mutations in the vast majority of schwannomas in
schwannomatosis patients10, 11. Similar to schwannomatosis
patients, loss of both Smarcb1 and Nf2 does not increase the
malignancy of mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox tumors
compared to mGFAP-Cre;Nf2flox/flox tumors with single Nf2 loss.
In contrast to NF2, schwannomas in schwannomatosis patients
are typically distinctly painful, rather than manifesting with
localized neurologic deficits2. Thus, Smarcb1 inactivation could
be responsible for the pain phenotype, as suggested by a report
showing that loss of Smarcb1 in adult mouse SC induces the
expression of a secreted factor that in turn increases TRPV1
expression and thermal sensitivity70.
In conclusion, we found that biallelic inactivation of Smarcb1
in the NC leads to the development of PNS and meningeal RTs,
thus identifying the cell of origin for these RT subsets in an early
NC population. We also defined an early spatio-temporal window
during which Smarcb1 loss results in malignant tumor formation
and showed that biallelic Nf2 loss is necessary and Smarcb1 loss
is dispensable for schwannoma formation. This mouse
model developing schwannomas with the same underlying gene
mutations found in schwannomatosis patients will prove
invaluable for the study of other schwannomatosis-associated
phenotypes, such as neuropathic pain.
Methods
Mice and genotyping. All mouse strains were maintained on FVB/N genetic
background. Mice were monitored twice a week for 24 months or until a tumor or
evidence of a tumor (paralysis, swelling, lethargy) was observed. All animal care
and experimentation were performed with the approval of the Institutional Animal
Care and Use Committees under protocol number HE1175-10-02. Smarcb1del/+
mice were obtained by breeding mGFAP-Cre;Smarcb1flox/+ males (expressing Cre
in the germline, http://www.jax.org/strain/024098) with wild-type FVB females.
mGFAP-Cre;Smarcb1del/flox mice were obtained by breeding mGFAP-Cre;
Smarcb1flox/+ males with Smarcb1flox/flox females. Mice were genotyped by PCR
amplification of DNA extracted from tail biopsies using the primers cre-s1
(5′-ACA TGT TCA GGG ATC GCC AG-3′) and cre-a1 (5′-TAA CCA GTG AAA
CAG CAT TGC-3′) for the Cre transgene, 407Fbis (5′-GGA AAA TCT AGA AAG
CAC AAA TGA-3′) and 408R (5′-TGT AGT CTA GGC TGG GTG TG-3′) for the
Smarcb1WT and Smarcb1flox alleles, 407Fbis and 416rbis (5′-CCT GGG GCA GCT
CTC TAC A-3′) for the Smarcb1del allele, NF2Flox2-S (5′-CTT CCC AGA CAA
Rhabdoid tumor
No tumor
No tumor
No tumor
Schwannoma
Nf2Smarcb1
Tumor type
observed in
mouse model
E13.5
E12.5
No tumor+/– +/+
E9.5
1st step 2nd step 3rd step
Neural
crest cell 
Schwann
cell
precursor
Immature
Schwann
cells
Pro-myelin
Schwann cells
Myelinating
Schwann cells
+/+
+/+
+/+
+/–
–/–
–/–
–/–
–/–
–/–
–/–
Corresponding human gene
inactivation steps
Combinations of mouse
gene inactivation
Early
Late
4-hit/3-step
mechanism
2-hit
mechanism
Non-myelinating
Schwann cells
Schwannoma-/–+/+ 2-hit
mechanism
No tumor+/–+/+
E13.5
No tumor+/+–/–*
P0-CreC;Smarcb1flox/+ and P0-CreB;Smarcb1flox/+
P0-CreC;Smarcb1flox/flox and P0-CreB;Smarcb1flox/flox
DHH-Cre;Smarcb1flox/flox
mGFAP-Cre;Smarcb1del/flox
mGFAP-Cre;Smarcb1flox/flox
mGFAP-Cre;Smarcb1flox/flox;Nf2flox/+
mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox
mGFAP-Cre;Nf2flox/+
mGFAP-Cre;Nf2flox/flox
a
b
Fig. 7 Proposed model of schwannoma versus RT initiation in the NC-derived SC lineage. Schematic illustration of the different combinations of mouse
genotypes modeling different steps of the human 4-hit/3-step mechanism sequence and corresponding tumor phenotypes. a Smarcb1 loss in early NC
results in RT development in P0-CreC;Smarcb1flox/flox mice, but is not tumorigenic when occurring at later SC developmental stages (DHH-Cre;Smarcb1flox/flox
and mGFAP-Cre;Smarcb1flox/flox mice). Thus, loss of Smarcb1 does not contribute to schwannoma development in mGFAP-Cre;Smarcb1flox/flox;Nf2flox/flox mice
where Nf2 loss in the SC lineage is sufficient for tumor initiation, as b in mGFAP-Cre;Nf2flox/flox mice. *germline Smarcb1 allele inactivation
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GCA GGG TTC-3′) and NF2Flox2-A (5′-GAA GGC AGC TTC CTT AAG TC-3′)
for the Nf2WT and Nf2flox alleles and Z1 (5′-GCG TTA CCC AAC TTA ATC G-3′)
and Z2 (5′-TGT GAG CGA GTA ACA ACC-3′) for the AZCL transgene.
Magnetic resonance imaging. Mice were anesthetized with isoflurane throughout
the imaging procedure. Mice were inserted in the prone position into a small
animal MRI scanner (PharmaScan 300; Bruker BioSpin Division, Billerica, MA,
USA) 7 Tesla magnet using the 19-mm inner diameter transmit receive coil.
ParaVision 4.0 scanner software (BRUKER BioSpin MRI GmbH, Ettlingen,
Germany) was set to use Rapid Acquisition with Relaxation Enhancement (RARE)
spin echo sequence for fast T2-weighted imaging (TE 50, TR 3000, RARE Factor 8)
with a 256 × 256 in-plane matrix and a 2.56-cm field of view. After scanning,
if needed, mice were gently warmed on a thermostatically controlled heating
pad until awake enough to be returned to their home cage. MRI images were
reconstructed at native resolution and analyzed with OsiriX (Open-Source
Software for Navigating in Multidimensional DICOM Images) image analysis
software packages.
H&E staining, immunohistochemistry, X-gal staining and cell counting.
Hematoxylin and eosin staining was performed on 3.5-µm-thick sections prepared
from paraffin blocks of formalin-fixed tissues. Immunohistochemistry was
performed on 9 P0-CreC;Smarcb1flox/flox representative tumors (3 tumors per
histological pattern) and 7 representative schwannomas from P0-CreC;Nf2flox/flox
mice (Fig. 3 and Supplementary Table 1). A standard protocol was used with
primary antibodies incubated 1 h at room temperature: cytokeratin (1/500, Dako,
M3515), FABP7 (1/1000, Abcam, ab32423), GFAP (1/3000, Dako, Z0334), Ki-67
(1/1000, BD Pharmingen, 556003), merlin (1/400, Cell Signaling Technology,
#6995), neurofilament triplet proteins (1/500, Enzo Life Sciences, BML-NA1223),
PGDS (1/1000, Santa Cruz Biotechnology, sc-14826), S100 (1/10000, Dako, Z0311),
SMA (1/200, BioCare Medical, CME 305), SMARCB1 (1/200, BD Transduction
Laboratories, 612110), vimentin (1/200, Cell Signaling Technology, #5741). Bioti-
nylated secondary anti-rabbit, anti-mouse (Vector Laboratories, Burlingame, CA)
or anti-goat (Dako) IgG antibodies were incubated 30 min at room temperature.
Immunoreactivity was semi-quantitatively scored based on the percentage of
positive tumor cells (few, foci or majority of positive cells) and the intensity of
staining (weak, moderate or strong).
To assess cell proliferation, bromodeoxyuridine (50 mg/kg body weight)
was administrated 4 h before dissection of the tissues. Incorporation of BrdU
was then revealed by immunohistochemistry with BrdU antibody (Fitzgerald
Industries International, 20-BS17) and secondary anti-sheep antibody (Jackson
ImmunoResearch Laboratories, West Grove, PA).
For X-gal staining, tissues were frozen in OCT compound (Tissue-Tek, 4583)
on dry ice. Frozen sections of 10 µm were fixed in 2% formaldehyde and 0.2%
glutaraldehyde in 1X PBS for 10 min at room temperature. Fixed tissues were
washed three times in 1X PBS, and incubated overnight at 37 °C in the staining
solution (5 mM K3[Fe(CN)6], 5 mM K4[Fe(CN)6], 2 mM MgCl2 and 2 mg/ml X-gal
in PBS). After staining, tissues were washed twice in 1× PBS and counterstained
with Nuclear Fast Red for 1–2 min.
For DRG cell count, 5–12 DRGs of the cervical and/or thoracic spine were
selected from 3–5 mice per genotype using a light microscope Axio Imager M1
(Zeiss). The region of interest (ROI) containing ganglion cells was manually
demarcated on captured images of 20× magnification fields. The Axiovision
software was used to determine the surface and the cells count in the ROI. All
histopathological analysis was performed in blind under the guidance of an
experienced pathologist.
PCR. PCR amplification was performed on DNA extracted from multiple tissues
using the primers cre-s1 and cre-a1 for the Cre transgene, 407Fbis and 408R for the
Smarcb1WT and Smarcb1flox alleles, 407Fbis, 408R, and 416R (5′-GCC ACC AGC
CAG ATG TCA TAC-3′) for the Smarcb1flox and Smarcb1del alleles in the tumors,
Ini1DelAf (5′-AAG CAC AAA TGA GAG AAA ACG TA-3′) and Ini1DelBr
(5′-TGC CAC CAG CCA GAT GTC A-3′) with Hotmaster Taq DNA polymerase
for the Smarcb1del allele in the PCR for all the tissues.
RNA-Seq and bioinformatics. RNA was isolated using the RiboPure kit
(Life Technologies) according to manufacturer’s instructions. RNA Libraries were
prepared using the TruSeq Stranded library preparation kit (Illumina) RNA after
RiboZero treatment for removal of ribosomal RNAs. After library preparation,
amplified double-stranded cDNA was fragmented into 125 bp (Covaris-S2,
Woburn, MA) DNA fragments, which were (200 ng) end-repaired to generate
blunt ends with 5′- phosphates and 3′- hydroxyls and adapters ligated. The purified
cDNA library products were evaluated using the Agilent Bioanalyzer (Santa Rosa,
CA) and diluted to 10 nM for cluster generation in situ on the HiSeq paired-end
flow cell using the CBot automated cluster generation system. All samples were
multiplexed into a single pool in order to avoid batch effects and sequenced using
an Illumina HiSeq 4000 sequencer (Illumina, San Diego, CA) yielding between 52
and 90 million reads per sample. Quality control was performed on base qualities
and nucleotide composition of sequences. Alignment to the M. musculus (mm10)
refSeq (refFlat) reference gene annotation was performed using the STAR spliced
read aligner with default parameters. Additional QC was performed after the
alignment to examine: the level of mismatch rate, mapping rate to the whole
genome, repeats, chromosomes, key transcriptomic regions (exons, introns, UTRs,
genes), insert sizes, AT/GC dropout, transcript coverage and GC bias. Between 80
and 85% (average 83%) of the reads mapped uniquely to the mouse genome and
only uniquely mapped reads were used for subsequent analyses. Total counts of
read-fragments aligned to candidate gene regions were derived using HTSeq
program (version 0.6.0, www.huber.embl.de/users/anders/HTSeq/doc/overview.
html) with mouse mm10 refSeq (refFlat table) as a reference and used as a basis for
the quantification of gene expression.
Microarray data from Johann et al.43 (GSE70678), Han et al.30 (GSE64019) and
Ng et al.44 (GSE68627) was downloaded from GEO and normalized using the
robust multiarray method (RMA). Gene symbols were used to match human and
mouse transcripts and merge expression datasets after averaging multiple probes
querying the same gene. Batch effects were corrected using ComBat and overall
quantile normalization was performed across data sets.
Hierarchical clustering of the top most variable genes (as ranked by s.d.)
was performed using the plotDendroAndColors function from the WGCNA
package. Weighted Gene Co-expression Network Analysis (WGCNA) was
conducted using the R package. Briefly, correlation coefficients were constructed
between expression levels of genes, and a connectivity measure (topological
overlap, TO) was calculated for each gene by summing the connection strength
with other genes. Genes were then clustered based on their TO, and groups of co-
expressed genes (modules) were identified. Each module was assigned a color, and
the first principal component (eigengene) of a module was extracted from the
module and considered to be representative of the gene expression profiles in a
module. The phenotypic trait of interest is then regressed on the eigengene to
examine whether there was a significant relationship between the module and the
trait.
The optimal number of clusters was determined using the non-negative matrix
factorization (NMF) method with the NMF R package, based on the top 5000 most
variable genes with standard NMF algorithm method (brunet) performed on 10
runs. The optimal numbers of clusters have been defined based on the maximum
cophenetic correlation score.
Quantitative RT-PCR. Reverse transcription was performed with 1 µg of the
same RNA samples used for RNA-Seq and the SuperScript IV VILO Master Mix
(Life Technologies) following the manufacturer’s instructions. Gene expression
levels were assessed by quantitative PCR using a QuantStudio 3 real-time PCR
system (Applied Biosystems) and TaqMan gene expression assays: Smarcb1
(Mm00448776_m1), Ezh2 (Mm00468464_m1) and Hprt (Mm00446968_m1, Life
Technologies). Relative expression was determined using the 2−ΔΔCt method with
Hprt expression as reference and normalized to a brain control sample.
Western blot. Tissues were snap-frozen in liquid nitrogen and stored at −80 °C.
Pulverized frozen tumor samples were lysed in radioimmunoprecipitation assay
(RIPA) buffer and the total proteins were extracted, separated, and transferred
using standard procedures. Antibodies were purchased from BD Transduction
Laboratories: SMARCB1 (1/500, 612110); Cell Signaling Technology: Akt (1/2000,
#9272), P-Akt (Ser473) (1/2000, #4060), CDK4 (1/2000, #2906), CDK6 (1/2000,
#3136), Cyclin D1 (1/3000, #2926), merlin (1/1000, #6995), p27 (1/1000, #2552),
P-Rb (1/1000, #8516), S6 (1/1000, #2317), P-S6 (Ser 235/236) (1/4000, #4858),
4E-BP1 (1/2000, #9452); Novus Biologicals: GAPDH (1/5000, NB300-221),
PTCH1 (1/1000, MAB41051), RB1 (1/50, NB120-3077), SHH (1/500, AF464);
R&D Systems: GLI-1 (1/1000, AF3455); Santa Cruz Biotechnology: p16 (1/3000,
sc-1207) and Thermo Scientific: p21WAF1 (1/1000, MS-387-P0). All uncropped
scans of western blots are provided in Supplementary Fig. 7.
Statistical analysis. GraphPad Prism software version 5.0 (GraphPad Software,
San Diego, CA) was used to perform statistical analysis and construct
Kaplan–Meier survival curves. Mendelian birth incidence of mouse genotypes was
examined using chi-square test. Differences in survival of mouse genotypes were
analyzed by log-rank Mantel–Cox test. Two-tailed Student’s unpaired t-test was
used to determine significance between groups unless otherwise indicated. The
variance between the groups was not significantly different (F test). A P value of
< 0.05 was considered statistically significant. Results of the significance tests
are reported as follow: ns (non significant), *(P< 0.05), **(P< 0.01) and
***(P< 0.001). Error bars represent s.e.m.
Data availability. The RNA-Sequencing data presented in this study have been
deposited in NCBI Gene Expression Omnibus with the accession number
GSE94082. All other data supporting the findings of this study are available
in Supplementary Information Files and from the
corresponding author upon reasonable request.
Received: 30 August 2016 Accepted: 23 June 2017
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00346-5 ARTICLE
NATURE COMMUNICATIONS |8:  300 |DOI: 10.1038/s41467-017-00346-5 |www.nature.com/naturecommunications 11
References
1. Rorke, L. B., Packer, R. J. & Biegel, J. A. Central nervous system atypical
teratoid/rhabdoid tumors of infancy and childhood: definition of an entity.
J. Neurosurg. 85, 56–65 (1996).
2. MacCollin, M., Woodfin, W., Kronn, D. & Short, M. P. Schwannomatosis: a
clinical and pathologic study. Neurology. 46, 1072–1079 (1996).
3. Biegel, J. A. et al. Germ-line and acquired mutations of INI1 in atypical teratoid
and rhabdoid tumors. Cancer Res. 59, 74–79 (1999).
4. Versteege, I. et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric
cancer. Nature 394, 203–206 (1998).
5. Sévenet, N. et al. Constitutional mutations of the hSNF5/INI1 gene predispose
to a variety of cancers. Am. J. Hum. Genet. 65, 1342–1348 (1999).
6. Hulsebos, T. J. et al. Germline mutation of INI1/SMARCB1 in familial
schwannomatosis. Am. J. Hum. Genet. 80, 805–810 (2007).
7. Plotkin, S. R. et al. Update from the 2011 international schwannomatosis
workshop: from genetics to diagnostic criteria. Am. J. Med. Genet. A 161A,
405–416 (2013).
8. Smith, M. J. Germline and somatic mutations in meningiomas. Cancer Genet.
208, 107–114 (2015).
9. Smith, M. J. et al. Frequency of SMARCB1 mutations in familial and sporadic
schwannomatosis. Neurogenetics 13, 141–145 (2012).
10. Sestini, R., Bacci, C., Provenzano, A., Genuardi, M. & Papi, L. Evidence of a
four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-
associated schwannomas. Hum. Mutat. 29, 227–231 (2008).
11. Piotrowski, A. et al. Germline loss-of-function mutations in LZTR1 predispose
to an inherited disorder of multiple schwannomas. Nat. Genet. 46, 182–187
(2014).
12. Lee, R. S. et al. A remarkably simple genome underlies highly malignant
pediatric rhabdoid cancers. J. Clin. Invest. 122, 2983–2988 (2012).
13. Kieran, M. W. et al. Absence of oncogenic canonical pathway mutations in
aggressive pediatric rhabdoid tumors. Pediatr. Blood Cancer 59, 1155–1157
(2012).
14. Smith, M. J., Wallace, A. J., Bowers, N. L., Eaton, H. & Evans, D. G. SMARCB1
mutations in schwannomatosis and genotype correlations with rhabdoid
tumors. Cancer Genet. 207, 373–378 (2014).
15. Swensen, J. J. et al. Familial occurrence of schwannomas and malignant
rhabdoid tumour associated with a duplication in SMARCB1. J. Med. Genet. 46,
68–72 (2009).
16. Eaton, K. W., Tooke, L. S., Wainwright, L. M., Judkins, A. R. & Biegel, J. A.
Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid
tumors. Pediatr. Blood Cancer 56, 7–15 (2011).
17. Carter, J. M. et al. Epithelioid malignant peripheral nerve sheath tumor
arising in a schwannoma, in a patient with “neuroblastoma-like”
schwannomatosis and a novel germline SMARCB1 mutation. Am. J. Surg.
Pathol. 36, 154–160 (2012).
18. Morgan, M. B., Stevens, L., Patterson, J. & Tannenbaum, M. Cutaneous
epithelioid malignant nerve sheath tumor with rhabdoid features: a histologic,
immunohistochemical, and ultrastructural study of three cases. J. Cutan.
Pathol. 27, 529–534 (2000).
19. Strom, T., Kleinschmidt-Demasters, B. K., Donson, A., Foreman, N. K.
& Lillehei, K. O. Rare nerve lesions of non-nerve sheath origin: a 17-year
retrospective series. Arch. Pathol. Lab. Med. 133, 1391–1402 (2009).
20. Rizzo, D. et al. SMARCB1 deficiency in tumors from the peripheral nervous
system: a link between schwannomas and rhabdoid tumors? Am. J. Surg.
Pathol. 36, 964–972 (2012).
21. Beschorner, R. et al. Atypical teratoid-rhabdoid tumor spreading along the
trigeminal nerve. Pediatr. Neurosurg. 42, 258–263 (2006).
22. Verma, A. & Morriss, C. Atypical teratoid/rhabdoid tumor of the optic nerve.
Pediatr. Radiol. 38, 1117–1121 (2008).
23. Wang, X. et al. Atypical teratoid/rhabdoid tumor (AT/RT) arising from the
acoustic nerve in a young adult: a case report and a review of literature.
Medicine 94, e439 (2015).
24. Giovannini, M. et al. Schwann cell hyperplasia and tumors in transgenic mice
expressing a naturally occurring mutant NF2 protein. Genes Dev. 13, 978–986
(1999).
25. Giovannini, M. et al. Conditional biallelic Nf2 mutation in the mouse promotes
manifestations of human neurofibromatosis type 2. Genes Dev. 14, 1617–1630
(2000).
26. Caramel, J., Medjkane, S., Quignon, F. & Delattre, O. The requirement for
SNF5/INI1 in adipocyte differentiation highlights new features of malignant
rhabdoid tumors. Oncogene 27, 2035–2044 (2008).
27. Chai, J. et al. Tumor-specific cooperation of retinoblastoma protein family and
Snf5 inactivation. Cancer Res. 67, 3002–3009 (2007).
28. Chun, H. J. et al. Genome-wide profiles of extra-cranial malignant rhabdoid
tumors reveal heterogeneity and dysregulated developmental pathways. Cancer
Cell 29, 394–406 (2016).
29. Guidi, C. J. et al. Disruption of Ini1 leads to peri-implantation lethality and
tumorigenesis in mice. Mol. Cell. Biol. 21, 3598–3603 (2001).
30. Han, Z. Y. et al. The occurrence of intracranial rhabdoid tumours in mice
depends on temporal control of Smarcb1 inactivation. Nat. Commun. 7, 10421
(2016).
31. Klochendler-Yeivin, A. et al. The murine SNF5/INI1 chromatin remodeling
factor is essential for embryonic development and tumor suppression. EMBO.
Rep. 1, 500–506 (2000).
32. Venneti, S. et al. Malignant rhabdoid tumors express stem cell factors, which
relate to the expression of EZH2 and Id proteins. Am. J. Surg. Pathol. 35,
1463–1472 (2011).
33. Deisch, J., Raisanen, J. & Rakheja, D. Immunohistochemical expression
of embryonic stem cell markers in malignant rhabdoid tumors.
Pediatr. Dev. Pathol.: Off. J. Soc. Pediatr. Pathol. Paediatr. Pathol. Soc. 14,
353–359 (2011).
34. Roberts, C. W., Galusha, S. A., McMenamin, M. E., Fletcher, C. D.
& Orkin, S. H. Haploinsufficiency of Snf5 (integrase interactor 1) predisposes
to malignant rhabdoid tumors in mice. Proc. Natl Acad. Sci. USA 97,
13796–13800 (2000).
35. Roberts, C. W., Leroux, M. M., Fleming, M. D. & Orkin, S. H. Highly penetrant,
rapid tumorigenesis through conditional inversion of the tumor suppressor
gene Snf5. Cancer Cell 2, 415–425 (2002).
36. Gresh, L. et al. The SWI/SNF chromatin-remodeling complex subunit SNF5 is
essential for hepatocyte differentiation. EMBO J. 24, 3313–3324 (2005).
37. Judkins A. R., Eberhart C. G., Wesseling P. & Hasselblatt M. Atypical teratoid/
rhabdoid tumour. in World Health Organization Classification of Tumours of
the Central Nervous System (eds Louis D. N., Ohgaki H., Wiestler O. D. &
Cavenee W. K.). 4th edn, revised edn (IARC Press, 2016).
38. Judkins, A. R. Immunohistochemistry of INI1 expression: a new tool for old
challenges in CNS and soft tissue pathology. Adv. Anat. Pathol. 14, 335–339
(2007).
39. Kalamarides, M. et al. Identification of a progenitor cell of origin capable of
generating diverse meningioma histological subtypes. Oncogene 30, 2333–2344
(2011).
40. Margol, A. S. & Judkins, A. R. Pathology and diagnosis of SMARCB1-deficient
tumors. Cancer Genet. 207, 358–364 (2014).
41. Stemmer-Rachamimov, A. O. et al. Comparative pathology of nerve sheath
tumors in mouse models and humans. Cancer Res. 64, 3718–3724 (2004).
42. Jessen, K. R. & Mirsky, R. The origin and development of glial cells in
peripheral nerves. Nat. Rev. Neurosci. 6, 671–682 (2005).
43. Johann, P. D. et al. Atypical teratoid/rhabdoid tumors are comprised of three
epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29,
379–393 (2016).
44. Ng, J. M. et al. Generation of a mouse model of atypical teratoid/rhabdoid
tumor of the central nervous system through combined deletion of Snf5 and
p53. Cancer Res. 75, 4629–4639 (2015).
45. Hall, D. P. et al. TRPM3 and miR-204 establish a regulatory circuit that
controls oncogenic autophagy in clear cell renal cell carcinoma. Cancer Cell 26,
738–753 (2014).
46. Xiao, Q. et al. HDGF-related protein-3 is required for anchorage-independent
survival and chemoresistance in hepatocellular carcinomas. Gut 62, 440–451
(2013).
47. Li, R. K. et al. Lysyl oxidase-like 4 (LOXL4) promotes proliferation and
metastasis of gastric cancer via FAK/Src pathway. J. Cancer Res. Clin. Oncol.
141, 269–281 (2015).
48. Wilson, B. G. et al. Epigenetic antagonism between polycomb and SWI/SNF
complexes during oncogenic transformation. Cancer Cell 18, 316–328 (2010).
49. Lu, H. et al. Regulation and role of post-translational modifications of enhancer
of zeste homologue 2 in cancer development. Am. J. Cancer Res. 6, 2737–2754
(2016).
50. Kim, K. H. & Roberts, C. W. Mechanisms by which SMARCB1 loss drives
rhabdoid tumor growth. Cancer Genet. 207, 365–372 (2014).
51. Kadoch, C. & Crabtree, G. R. Mammalian SWI/SNF chromatin remodeling
complexes and cancer: mechanistic insights gained from human genomics. Sci.
Adv. 1, e1500447 (2015).
52. Simoes-Costa, M. & Bronner, M. E. Establishing neural crest identity: a gene
regulatory recipe. Development 142, 242–257 (2015).
53. Jaegle, M. et al. The POU proteins Brn-2 and Oct-6 share important functions
in Schwann cell development. Genes Dev. 17, 1380–1391 (2003).
54. Gregorian, C. et al. PTEN dosage is essential for neurofibroma development
and malignant transformation. Proc. Natl Acad. Sci. USA 106, 19479–19484
(2009).
55. Tao, J. et al. Deletion of astroglial Dicer causes non-cell-autonomous neuronal
dysfunction and degeneration. J. Neurosci. 31, 8306–8319 (2011).
56. Moreno, N. et al. Loss of Smarc proteins impairs cerebellar development.
J. Neurosci. 34, 13486–13491 (2014).
57. Boyd, C. et al. Alterations in the SMARCB1 (INI1) tumor suppressor gene in
familial schwannomatosis. Clin. Genet. 74, 358–366 (2008).
58. Hadfield, K. D. et al. Molecular characterisation of SMARCB1 and NF2 in
familial and sporadic schwannomatosis. J. Med. Genet. 45, 332–339 (2008).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00346-5
12 NATURE COMMUNICATIONS |8:  300 |DOI: 10.1038/s41467-017-00346-5 |www.nature.com/naturecommunications
59. Hadfield, K. D. et al. Rates of loss of heterozygosity and mitotic recombination
in NF2 schwannomas, sporadic vestibular schwannomas and schwannomatosis
schwannomas. Oncogene 29, 6216–6221 (2010).
60. Stemmer-Rachamimov, A. O. et al. Loss of the NF2 gene and merlin occur by
the tumorlet stage of schwannoma development in neurofibromatosis 2.
J. Neuropathol. Exp. Neurol. 57, 1164–1167 (1998).
61. Tsurusaki, Y. et al. Mutations affecting components of the SWI/SNF complex
cause Coffin-Siris syndrome. Nat. Genet. 44, 376–378 (2012).
62. Nagoshi, N. et al. Ontogeny and multipotency of neural crest-derived stem cells
in mouse bone marrow, dorsal root ganglia, and whisker pad. Cell Stem. Cell 2,
392–403 (2008).
63. Crone, S. A., Negro, A., Trumpp, A., Giovannini, M. & Lee, K. F. Colonic
epithelial expression of ErbB2 is required for postnatal maintenance of the
enteric nervous system. Neuron 37, 29–40 (2003).
64. Dho, Y. S. et al. Investigation of the location of atypical teratoid/rhabdoid
tumor. Child’s Nervous Syst.: Off. J. Int. Soc. Pediatric Neurosurg. 31, 1305–1311
(2015).
65. El-Nabbout, B., Shbarou, R., Glasier, C. M. & Saad, A. G. Primary diffuse
cerebral leptomeningeal atypical teratoid rhabdoid tumor: report of the first
case. J. Neurooncol. 98, 431–434 (2010).
66. Seeringer, A. et al. Synchronous congenital malignant rhabdoid tumor of the
orbit and atypical teratoid/rhabdoid tumor–feasibility and efficacy of
multimodal therapy in a long-term survivor. Cancer Genet. 207, 429–433 (2014).
67. Mulay, K. & Honavar, S. G. Primary, orbital, malignant extra-renal, non-
cerebral rhabdoid tumour. Orbit 33, 292–294 (2014).
68. Barresi, V. et al. Atypical teratoid rhabdoid tumor involving the nasal cavities
and anterior skull base. Neuropathol.: Off. J. Jpn Soc. Neuropathol. 36, 283–289
(2015).
69. Li, L. et al. Primary atypical teratoid/rhabdoid tumor of the spine in an adult
patient. Surg. Neurol. Int. 7, 27 (2016).
70. Widemann, B. C. et al. CTF meeting 2012: translation of the basic
understanding of the biology and genetics of NF1, NF2, and schwannomatosis
toward the development of effective therapies. Am. J. Med. Genet. A. 164A,
563–578 (2014).
Acknowledgements
We would like to thank Dr. Anat Stemmer-Rachamimov (Massachusetts General
Hospital and Harvard Medical School, Boston, MA) for histopathological review of
mouse schwannomas; Rosa Sierra, Fabrice Chareyre, Rocky Adams and Benedicte
Chareyre for technical support; Pr. Michel Kalamarides (Groupe Hospitalier
Pitié-Salpêtrière, Paris, France) for meningeal RT immunostainings; Gevorg Karapetyan
(Children’s Hospital, Los Angeles, CA) for mouse MRI services; Dr. Agnes Klonchendler
(The Hebrew University of Jerusalem, Jerusalem, Israel) for providing the Smarcb1flox
mouse strain; Dr. Dies N Meijer (Erasmus University Medical Center, Rotterdam,
Netherlands) for providing the DHH-Cre mouse strain; Dr. Michael V. Sofroniew
(University of California Los Angeles, Los Angeles, CA) for providing the mGFAP-Cre
mouse strain; Dr. Jaclyn A. Biegel for invaluable input on the project. This work
was supported by the Children’s Tumor Foundation Schwannomatosis awards No.
2008-02-007 and 2011-02-010 (M.G.); U.S. Army Medical Research and Materiel
Command, through the Neurofibromatosis Research Program under Award No.
W81XWH-10-1-0070 (J.V.); the NINDS Informatics Center for Neurogenetics and
Neurogenomics P30 NS062691 (G.C.); the House Research Institute and the Department
of Head and Neck Surgery at UCLA. Opinions, interpretations, conclusions and
recommendations are those of the author and are not necessarily endorsed by the
Department of Army.
Author contributions
J.V. designed the study, performed experiments, analyzed data and wrote the manuscript.
F.G. and G.C. performed the bioinformatics analyses. A.R.J. interpreted the histological
data and revised the manuscript. M.G. designed and supervised the study and wrote the
manuscript.
Additional information
Supplementary Information accompanies this paper at doi:10.1038/s41467-017-00346-5.
Competing interests: The authors declare no competing financial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2017
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00346-5 ARTICLE
NATURE COMMUNICATIONS |8:  300 |DOI: 10.1038/s41467-017-00346-5 |www.nature.com/naturecommunications 13
